A major new review published in The Lancet, one of the most rigorous to date, has found no evidence that taking acetaminophen — known clinically as paracetamol and commonly sold under brands such as Panadol — during pregnancy increases the risk of autism spectrum disorders, attention‑deficit/hyperactivity disorder (ADHD) or intellectual disability in offspring.

The findings add to a growing body of high‑quality research that rebuts earlier suggestions of a link between prenatal paracetamol exposure and later neurodevelopmental problems.

In Malaysia, and in most of the world outside the United States and Canada, acetaminophen is called paracetamol. Both names refer to the same drug; the chemical name is N‑acetyl‑p‑aminophenol, often abbreviated APAP. It is widely used as an analgesic — a pain reliever — and an antipyretic — a fever reducer. The terminology varies by country, but the compound is identical and the clinical recommendations apply regardless of the brand or regional name.

The review pooled results from dozens of the best available studies and placed particular emphasis on sibling‑comparison designs. Those studies compare children born to the same mother: one pregnancy exposed to paracetamol, the other not. Because siblings share genes, household environment and many parental characteristics, this approach reduces confounding that can mislead simpler observational studies. In total, the analyses included hundreds of thousands of children across cohorts assessed for autism, ADHD and intellectual disability.

The conclusion was straightforward. When sibling comparisons were used, there was no reliable association between maternal use of paracetamol during pregnancy and later diagnosis of autism, ADHD or intellectual disability. In short: earlier signals from less rigorous studies appear to dissipate under tighter scrutiny.

The topic has been politically charged particularly in the United States (US). Government statements and high‑profile litigation have raised alarm among pregnant people after suggestions emerged that routine use of paracetamol might elevate neurodevelopmental risk.

Those concerns prompted lawsuits alleging the pharmaceutical industry failed to warn consumers adequately. The new review challenges the medical basis for such claims.

At the same time, federal health authorities from the US have continued to voice caution. Some officials have maintained that concerns remain and urged careful consideration of all evidence, including biological plausibility and findings from some epidemiological studies that did report associations.

The recent review prompted disagreement between researchers and parts of the government. Researchers argued that the review’s sibling‑comparison method more effectively controls for shared familial and genetic factors that could otherwise produce spurious links. Federal officials of the US countered that the review did not settle causality questions and that various experts still consider a potential causal relationship plausible.

Many earlier studies reported small increases in the odds of autism or ADHD after prenatal paracetamol exposure. Those results worried clinicians and pregnant people alike. But observational research is vulnerable to confounding: the challenge of distinguishing the effects of a drug from the underlying condition that prompted its use. For example, fever, pain, infection or inflammatory conditions in pregnancy could themselves influence neurodevelopment. Genetics and maternal traits could play a role too.

Sibling‑comparison studies address these problems. By comparing siblings with differing exposure status, they effectively hold constant many genetic and family‑level environmental factors. If a genuine causal effect existed, the exposed sibling would show higher rates of disorder than the unexposed sibling. In the pooled sibling analyses, that pattern did not appear. The implication is that previously reported links are likely to reflect confounding by genetic or maternal factors, rather than a direct harmful effect of paracetamol.

Clinicians who treat pregnant patients commonly recommend paracetamol for short‑term relief of fever and pain. Fever in pregnancy is a recognised hazard and may carry greater risk to the foetus than the medication used to treat it. The review’s authors and other practising clinicians reaffirm that paracetamol remains an appropriate option when used as directed for common indications in pregnancy.

That said, best practice remains to use the lowest effective dose for the shortest necessary period. Discussing symptoms and treatment options with a clinician remains important. For many common pregnancy complaints — headache, musculoskeletal pain, low‑grade fever — paracetamol often represents the safest balance of benefit and risk.

This latest review is not an isolated finding. Other large, careful syntheses of the literature have reached similar conclusions. An umbrella review of systematic reviews concluded that the evidence does not clearly support a link between maternal paracetamol use and offspring autism or ADHD, highlighting methodological limitations in studies that suggested associations. Independent large cohort analyses have also failed to produce consistent evidence of harm when accounting for confounding.

The scientific consensus does not, however, rest solely on null findings. Researchers continue to explore biological pathways and the complexities of neurodevelopment. Environmental influences, genetic susceptibility and interactions between the two remain active areas of study.

Current understanding emphasises that autism and related neurodevelopmental conditions arise from a mix of genetic predisposition and environmental factors. No single environmental exposure has been identified as a definitive cause in most cases.

The debate over paracetamol shares some features with the long‑standing controversy about vaccines and autism. Decades of rigorous research, including very large population studies, have shown no causal link between childhood vaccinations and autism.

Recent, large‑scale evaluations continue to reinforce vaccine safety, including the safety of common vaccine components. Public health authorities stress the importance of following recommended vaccination schedules to prevent outbreaks of vaccine‑preventable diseases, which can cause serious harm.

When pregnant people worry about medication‑related harms to their child, the fear is understandable. Pregnancy spurs intense focus on every choice that might impact the unborn baby. But risk evaluation requires weighing the hazards of untreated maternal illness against the potential downsides of medication. Fever, severe pain and uncontrolled infection can threaten maternal and foetal wellbeing. For such conditions, paracetamol often provides a safer course than leaving symptoms unaddressed. Always consult your doctor for medical advice.

At a population level, the new review suggests that maternal paracetamol use during pregnancy is unlikely to be a major contributor to the incidence of autism, ADHD or intellectual disability.

Put differently: public‑health efforts to address those conditions should concentrate on the multiple established genetic and environmental factors known to influence neurodevelopment, rather than prioritising paracetamol exposure as a main culprit.

No single study can eradicate uncertainty. Limitations inherent to observational research cannot be fully eliminated. Sibling comparison reduces many confounders but introduces others: for example, pregnancies spaced widely apart may involve changes in maternal health, environment or behaviour that could influence outcomes. Measurement error in assessing dose, timing and duration of paracetamol use remains an issue. Some researchers also point to potential biological mechanisms that merit laboratory and experimental investigation.

Scientific debate therefore continues, but increasingly it proceeds within tighter bounds. The strongest available human evidence, using methods designed to handle familial confounding, shows no signal of harm. Where disagreement exists, it centres on interpretation and the degree of caution warranted, not on dramatic, consistent new signals of risk.

If you are pregnant or planning pregnancy and you use over‑the‑counter pain relief:

• Describe the symptoms to your medical doctor that prompt you to use paracetamol: fever, type and location of pain, duration and severity.
• Discuss with your doctor non‑drug measures where appropriate: rest, hydration, physical adjustments, or targeted therapies recommended by your clinician.
• When medication is needed, discuss dosing and duration with your doctor such as the use of lowest effective dose for the shortest period. Do not exceed recommended daily limits.
• Manage fever actively with your doctor’s advicee. Persistent or high fever during pregnancy warrants clinical assessment because fever itself can be harmful.

The controversy has had legal as well as clinical consequences. Lawsuits alleging that manufacturers failed to warn about prenatal risks capitalised on earlier observational findings.

The new review will likely influence legal arguments and public messaging, but litigation tends to proceed on timelines independent of scientific consensus. Policymakers and regulators may also reassess public statements in light of accumulating evidence.

Science advances by refining tools, questioning earlier findings and testing alternative explanations. The most rigorous human evidence now available indicates that maternal paracetamol use during pregnancy is unlikely to raise the risk of autism, ADHD or intellectual disability in children.

That conclusion rests heavily on sibling‑comparison studies that account for shared genetic and familial factors that may have confounded earlier research.

For clinicians and pregnant people, the sensible approach remains unchanged: treat significant fever and pain, consult your healthcare professional, and use paracetamol responsibly and sparingly.

Public‑health priorities for preventing neurodevelopmental disorders should continue to address known genetic risks and modifiable environmental exposures with established effects, while researchers explore remaining uncertainties about mechanisms and interactions.